.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical evaluations of Finerenone cardiovascular outcomes emphasize the importance of statistical robustness in trial results. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, effectively reduces risk for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Researchers recently applied fragility metrics to quantify the reliability of these cardiovascular benefits across major phase 3 randomized controlled trials. This approach provides a clearer understanding of how many event changes would be necessary to alter the significance of published data.
The analysis focused on three primary data sources: the FIDELIO-DKD and FIGARO-DKD trials, along with the pooled FIDELITY analysis. Furthermore, the investigators calculated the fragility index (FI) and the reverse fragility index (RFI) for composite and individual outcomes. The primary composite cardiovascular outcome—including CV death, myocardial infarction, stroke, and heart failure hospitalization—showed significant reduction in FIDELITY. With a fragility index of 38, this pooled analysis suggests a relatively robust benefit. In contrast, the FIDELIO-DKD trial reported a fragility index of 4, indicating that its composite results are more sensitive to small changes in event numbers.
Moreover, heart failure hospitalization emerged as the most consistent and robust individual benefit. The FIDELITY analysis showed a hazard ratio of 0.78 for this endpoint, supported by a fragility index of 23. Consequently, while the composite benefits are clear, individual outcomes such as cardiovascular death, myocardial infarction, and stroke showed numerical favorability but lacked statistical significance. These specific endpoints displayed low reverse fragility indices, ranging mostly from 1 to 3. This means only a few event changes could have potentially reached statistical significance, yet the current data remains fragile for these parameters.
Therefore, combining fragility metrics with standard hazard ratios and absolute risk reductions offers a more nuanced view of drug efficacy. Clinicians should recognize that while Finerenone robustly protects against heart failure hospitalization, its impact on other specific atherosclerotic events is less certain. Such insights are crucial for personalized treatment planning in the high-burden CKD and T2DM population in India.
The fragility index represents the minimum number of patients who would need to have a different outcome (moving from a non-event to an event) to turn a statistically significant result into a non-significant one. A higher index indicates a more robust trial result.
Finerenone demonstrates a robust and consistent reduction in heart failure hospitalization among patients with T2DM and CKD. In pooled analyses, this benefit remains statistically stable even when analyzed through fragility metrics.
The reverse fragility index (RFI) applies to results that are not statistically significant. It indicates how many patients would need to change from an event to a non-event to make the result statistically significant. It measures how close a result is to achieving significance.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Zuin M et al. Fragility Analysis of Cardiovascular Outcomes with Finerenone in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Eur J Heart Fail. 2026 May 05. doi: undefined. PMID: 42087276.
2. Agarwal R et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484.
3. Bakris GL et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229.
4. Pitt B et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A fragility analysis of Finerenone trials reveals robust heart failure benefits but suggests caution regarding other cardiovascular endpoints in T2DM and CK...
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
